Aurélie Cobat - Infectious Diseases

Author Information

Aurélie Cobat is a researcher affiliated with the Laboratory of Human Genetics of Infectious Diseases, a part of INSERM U1163 located at the Necker Branch in Paris, France. Her work focuses on the genetic and immunological factors influencing infectious diseases, with particular attention to COVID-19 and its related complications.

Research Contributions

Aurélie Cobat has made significant contributions to understanding the genetic basis of infectious diseases, particularly in the context of COVID-19. Her research includes investigations into autoantibodies neutralizing type I interferons, genetic variants influencing susceptibility to severe COVID-19, and the genetic determinants of critical COVID-19 pneumonia. She has also explored genetic associations with other infectious diseases, such as Mycobacterium tuberculosis and leprosy.

Aliases

Aurélie Cobat is also known by several aliases, including A Cobat, A. Cobat, Aurelie Cobat, and Aurelié Cobat.

Publication and Citation Metrics

Metric	Value
Total Citation Count	9,919
H-index	41
Total Paper Count	145

Publications:

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital

DOI: 10.1007/s10875-021-01203-3

Year: 2022

A common TMPRSS2 variant has a protective effect against severe COVID-19

DOI: 10.1016/j.retram.2022.103333

Year: 2022

The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

DOI: 10.21203/rs.3.rs-1225906/v1

Year: 2022

Human genetic and immunological determinants of critical COVID-19 pneumonia.

DOI: 10.1038/s41586-022-04447-0

Year: 2022

Biochemically deleterious human NFKB1 variants underlie an autosomal dominant form of common variable immunodeficiency.

DOI: 10.1084/jem.20210566

Year: 2021

Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance

DOI: 10.1007/s10875-020-00930-3

Year: 2021

Genome-wide association study of resistance to Mycobacterium tuberculosis infection identifies a locus at 10q26.2 in three distinct populations

DOI: 10.1371/journal.pgen.1009392

Year: 2021

Early onset leprosy reveals a joint effect of LRRK2 and NOD2 variants

DOI: 10.1101/2021.03.25.21253623

Year: 2021

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years and account for ~ 20% of COVID-19 deaths

DOI: 10.1126/sciimmunol.abl4340

Year: 2021

Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia.

DOI: 10.1172/JCI152474

Year: 2021

What are the Challenges in Controlling Schistosomiasis?

What Are the Side Effects of Antivirals?

What is the global impact of Plasmodium falciparum malaria?

What Challenges Does the Global Fund Face?

What are Common Symptoms of Infectious Diseases?

How Does Chronic Inflammation Affect Infectious Diseases?

How is Dengue Hemorrhagic Fever Diagnosed?

What Diseases are Transmitted by Aedes Albopictus?

Are There Any Vaccines for Malaria?

What is the Role of the Zika Virus in Microcephaly?

Partnered Content Networks

Relevant Topics